



Assessing response to RT/CT in colorectal cancer



Phil Quirke Pathology and tumour biology Leeds University

Pathology, Anatomy and Tumour Biology Leeds Institute of Cancer and Pathology





Tumour response - variable

- Will the tumour respond?
- How much?
- How quickly and for how long?

Some response may still be beneficial e.g. CRM +ve to negative

40% no response - why?






Pathology, Anatomy and Tumour Biology

Response and stage



- Rodel et al 2005 better response in earlier stage
- Greccar 2 better response in early stage
- Perez cT2 vs cT3 pCR 67% vs 20%
- FDGF cT2 vs cT3 pCR 39% vs 9%



Rodel et al 2005

Pathology, Anatomy and Tumour Biology



Factors that influence response



- Degree of response may depend on:
 - Type of pre-operative therapy
 - Delay time between last dose and surgery
 - Quality of pathological assessment



Operation delay	/
1 week	
6 weeks	
8-12 weeks	
Watch and wait	
•	

Length of cycles

Number of cycles

Dose of RT

Dose/combination of drugs

Therapy

Radiotherapy alone (short course / long course)

Chemoradiotherapy (1 or 2 drugs / biologicals)

Chemotherapy alone (multiple drugs)

Pathology, Anatomy and Tumour Biology



d prefix

- We recommend that individual patients would have a 'd' prefix denoting the interval between the start of treatment and its assessment, local excision or definitive surgical procedure.
- This interval should be denoted in days, and might vary between 10 and 119 days e.g ypd10 T2 ypN0 or ypd119 T2 ypN0. Thus the overall trial could be analysed according to a median/mean 'd' score.

Dis Colon Rectum. 2015 Jun;58(6):613-6. doi: 10.1097/DCR.000000000000356.

The D prefix: toward a reproducible validated alternative end point in rectal cancer.

<u>Glynne-Jones R</u>¹, <u>West NP</u>, <u>Quirke P</u>.


Pathology, Anatomy and Tumour Biology





Morphology



- Macroscopic lesion
 - Ulcer 13% ypCR
 - Scar 59% ypCR
 - No visible defect 66% ypCR
- Differential microscopic morphological response
 - Fragmentation
 - Shrinkage towards the lumen
 - Mucinous change








Fragmentation






Pathology, Anatomy and Tumour Biology





Shrinkage to the lumen






0999999

Pathology, Anatomy and Tumour Biology

Mucoid pCR






000000

Pathology, Anatomy and Tumour Biology

Response in colon cancer to chemotherapy



- Foxtrot trial advanced primary colon cancer
 - 6 weeks preoperative chemotherapy vs none



Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial


FOxTROT Collaborative Group*

Lancet Oncology 2012;13:1152-60



Pathology, Anatomy and Tumour Biology

Colon cancer








Pathology, Anatomy and Tumour Biology

Colon cancer - fragmentation










Pathology, Anatomy and Tumour Biology

Regression to the lumen




Pathology, Anatomy and Tumour Biology



Mucoid change






Pathology, Anatomy and Tumour Biology



Heterogeneity of response






Pathology, Anatomy and Tumour Biology



Complete response Excellent response



Pathology, Anatomy and Tumour Biology






Tumour response – TNM8



Mandard



RESIDUAL CANCER CELLS

TNM8 Ryan et al

 Table 20.2
 Modified Ryan scheme for tumor regression score

Description	Tumor regression score
No viable cancer cells (complete response)	0
Single cells or rare small groups of cancer cells (near-complete response)	1
Residual cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response)	2
Extensive residual cancer with no evident tumor regression (poor or no response)	3
(Adapted from Ryan et al ^{11,12,60} with permission).	



Pathology, Anatomy and Tumour Biology

Post therapy staging




- Standardised dissection method
- Clear margin/CRM 1mm
- ypdTNM
- Degree and pattern of response
- ?% tumour cell density



Pathology, Anatomy and Tumour Biology

Recommended method

- Inking margins
- Cross sectional slicing •
 - Good visualisation
 - Assessment of CRM
 - Assessment of quality of surgery
 - Allows comparison to MRI
















Dissection method

- Routine
 - 5 blocks 1 H&E
 - Levels x3 (20 slides)
 - No tumour embed all of area where tumour was present +8 blocks
 - Levels x3 (32 slides)
 - Total = 52 slides













West et al Tumour cell density – more sensitive predictor of response and helpful in improving MRI prediction of response?



300 points




Pathology, Anatomy and Tumour Biology


Short course 5x5 surgery at 1 week



Greatest tumour cell
 density



• Whole tumour



Pathology, Anatomy and Tumour Biology

0999999

Summary

- Response seen depends on stage, treatment and operation timing
- Use the d classification in studies
- Morphological changes seen in RT/CT and CT alone in rectum and colon appear similar
- TNM8 fusion of no response/mild response
- Key is to use standard dissection method to assess response
- Is tumour cell density a better quantitative approach to assessing the effectiveness of new treatments in trials?



Thanks to:

- Pathologists Nick West, Emma Tinkler, Heike Grabsch, Iris Nagtegaal
- Radiotherapy colleagues David Sebag-Montefiore, Rob Glynne-Jones, Corrie Marijnen
- Surgical collegues Harm Rutten, Paul Finan
- CORE and CR07 trialists
- Funders Yorkshire Cancer Research, MRC



Pathology, Anatomy and Tumour Biology

